Your browser doesn't support javascript.
loading
Modulation of Nogo receptor 1 expression orchestrates myelin-associated infiltration of glioblastoma.
Hong, Jun-Hee; Kang, Sangjo; Sa, Jason K; Park, Gunwoo; Oh, Young Taek; Kim, Tae Hoon; Yin, Jinlong; Kim, Sung Soo; D'Angelo, Fulvio; Koo, Harim; You, Yeonhee; Park, Saewhan; Kwon, Hyung Joon; Kim, Chan Il; Ryu, Haseo; Lin, Weiwei; Park, Eun Jung; Kim, Youn-Jae; Park, Myung-Jin; Kim, Hyunggee; Kim, Mi-Suk; Chung, Seok; Park, Chul-Kee; Park, Sung-Hye; Kang, Yun Hee; Kim, Jong Heon; Saya, Hideyuki; Nakano, Ichiro; Gwak, Ho-Shin; Yoo, Heon; Lee, Jeongwu; Hur, Eun-Mi; Shi, Bingyang; Nam, Do-Hyun; Iavarone, Antonio; Lee, Seung-Hoon; Park, Jong Bae.
Afiliación
  • Hong JH; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Kang S; Department of Clinical Research, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Sa JK; Department of Clinical Research, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Park G; BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
  • Oh YT; Department of Clinical Research, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Kim TH; Institute for Cancer Genetics, Columbia University Medical Center, New York, New York 10032, USA.
  • Yin J; Department of Clinical Research, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Kim SS; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • D'Angelo F; Henan and Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, China.
  • Koo H; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • You Y; Institute for Cancer Genetics, Columbia University Medical Center, New York, New York 10032, USA.
  • Park S; Department of Clinical Research, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Kwon HJ; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
  • Kim CI; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Ryu H; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Lin W; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Park EJ; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Kim YJ; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Park MJ; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Kim H; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Kim MS; Division of Translational Science, Research Institute, National Cancer Center, Goyang, Korea.
  • Chung S; Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
  • Park CK; Department of Biotechnology, School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Korea.
  • Park SH; Department of Neurosurgery and Samsung Advanced Institute for Health Sciences and Technology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, Korea.
  • Kang YH; School of Mechanical Engineering, Korea University, Seoul, Korea.
  • Kim JH; Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.
  • Saya H; Department of Pathology Seoul National University College of Medicine, Seoul, Korea.
  • Nakano I; Eulji Biomedical Science Research Institute, Eulji University School of Medicine, Daejeon 34824, Korea.
  • Gwak HS; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Yoo H; Division of Gene Regulation, IAMR, Keio University School of Medicine, Tokyo, Japan.
  • Lee J; Research and Development Center for Precision Medicine, Tsukuba University, Japan.
  • Hur EM; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Shi B; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  • Nam DH; Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Iavarone A; Department of Neuroscience, Collage of Veterinary Medicine, Research Institute for Veterinary Science and BK21 PLUS Program for Creative Veterinary Science Research, Seoul National University, Seoul, Korea.
  • Lee SH; Henan and Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, China.
  • Park JB; Department of Neurosurgery and Samsung Advanced Institute for Health Sciences and Technology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, Korea.
Brain ; 144(2): 636-654, 2021 03 03.
Article en En | MEDLINE | ID: mdl-33479772
ABSTRACT
As the clinical failure of glioblastoma treatment is attributed by multiple components, including myelin-associated infiltration, assessment of the molecular mechanisms underlying such process and identification of the infiltrating cells have been the primary objectives in glioblastoma research. Here, we adopted radiogenomic analysis to screen for functionally relevant genes that orchestrate the process of glioma cell infiltration through myelin and promote glioblastoma aggressiveness. The receptor of the Nogo ligand (NgR1) was selected as the top candidate through Differentially Expressed Genes (DEG) and Gene Ontology (GO) enrichment analysis. Gain and loss of function studies on NgR1 elucidated its underlying molecular importance in suppressing myelin-associated infiltration in vitro and in vivo. The migratory ability of glioblastoma cells on myelin is reversibly modulated by NgR1 during differentiation and dedifferentiation process through deubiquitinating activity of USP1, which inhibits the degradation of ID1 to downregulate NgR1 expression. Furthermore, pimozide, a well-known antipsychotic drug, upregulates NgR1 by post-translational targeting of USP1, which sensitizes glioma stem cells to myelin inhibition and suppresses myelin-associated infiltration in vivo. In primary human glioblastoma, downregulation of NgR1 expression is associated with highly infiltrative characteristics and poor survival. Together, our findings reveal that loss of NgR1 drives myelin-associated infiltration of glioblastoma and suggest that novel therapeutic strategies aimed at reactivating expression of NgR1 will improve the clinical outcome of glioblastoma patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma / Receptor Nogo 1 / Vaina de Mielina Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans Idioma: En Revista: Brain Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma / Receptor Nogo 1 / Vaina de Mielina Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans Idioma: En Revista: Brain Año: 2021 Tipo del documento: Article
...